A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.
Jethro L HuOluwaseun A OmofoyeJeremy D RudnickSungjin KimMourad TighiouartSurasak PhuphanichHongqiang WangMia MazerToni GanawayRay M ChuChirag G PatilKeith L BlackStephen L ShiaoRong-Fu WangJohn S YuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In this trial, treatment of newly diagnosed and recurrent glioblastoma with autologous dendritic cell vaccine pulsed with lysate derived from an allogeneic stem-like cell line was safe and well-tolerated. Clinical outcomes add to the body of evidence suggesting that immunotherapy plays a role in the treatment of glioblastoma.